Sugi Predict

Sugi Predict / Compounds / SCHEMBL1270523

SCHEMBL1270523

SCHEMBL1270523

CC(C)(C)OC(=O)N1CCc2ccc(C(=O)O)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM4 P08173 1/20 0.50
▸ DRD2 P14416 1/20 0.50
▸ HTR7 P34969 1/20 0.50
▸ ESR2 Q92731 1/20 0.46
▸ NR1H2 P55055 1/20 0.45
▸ DHODH Q02127 1/20 0.43
▸ NOTUM Q6P988 1/20 0.43
▸ KDM1A O60341 1/20 0.42
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ GPR119 Q8TDV5 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPT P10636 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MYC P01106 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ BRD4 O60885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29939759 1.00 CHRM4 (0.50) CHRM4DRD2HTR7ESR2NR1H2
SCHEMBL3576898 0.93 ALDH1A1 (0.45) CHRM4DRD2HTR7ESR2NR1H2
SCHEMBL29631022 0.93 ALDH1A1 (0.45) CHRM4DRD2HTR7ESR2NR1H2
SCHEMBL380505 0.89 DHODH (0.49) CHRM4DRD2HTR7ESR2DHODH
SCHEMBL30527088 0.89 DHODH (0.49) CHRM4DRD2HTR7ESR2DHODH
SCHEMBL3571209 0.87 HDAC1 (0.53) CHRM4DRD2HTR7ESR2NR1H2
SCHEMBL29940282 0.87 HDAC1 (0.53) CHRM4DRD2HTR7ESR2NR1H2
SCHEMBL6625750 0.84 LMNA (0.46) CHRM4DRD2HTR7ESR2NR1H2
SCHEMBL23063860 0.83 DRD2 (0.52) CHRM4DRD2HTR7ESR2NR1H2
SCHEMBL3905057 0.83 ESR2 (0.61) CHRM4DRD2HTR7ESR2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313292-B1 INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS CHIESI FARM SPA (IT) 2026-02-18 — — EP disclosed
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed
US-20240190847-A1 INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-06-13 — — US disclosed
EP-4313292-A1 INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP disclosed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP disclosed
US-20230416251-A1 SPIROCYCLIC COMPOUNDS C4 THERAPEUTICS, INC. (US) 2023-12-28 — — US disclosed
CN-117120434-A Indoline derivatives as DDR1 and DDR2 inhibitors 奇斯药制品公司 2023-11-24 — — CN disclosed
EP-2172447-A1 AMIDE COMPOUND Astellas Pharma Inc. (JP) 2010-04-07 — — EP disclosed
EP-1926711-A1 NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE F.HOFFMANN-LA ROCHE AG (CH) 2008-06-04 — — EP disclosed
WO-2007031429-A1 NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE F. HOFFMANN-LA ROCHE AG (CH) 2007-03-22 — — WO disclosed
US-20070060567-A1 Novel indolyl derivatives which are L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-03-15 — — US disclosed
US-20030232860-A1 Medicine comprising dicyanopyridine derivative ASTELLAS PHARMA INC. (JP) 2003-12-18 — — US disclosed
EP-1302463-A1 MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-04-16 — — EP disclosed
US-6316482-B1 FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-13 — — US disclosed
US-6207693-B1 Benzamide derivatives having a vasopressin antagonistic activity FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-27 — — US disclosed
EP-0946519-A1 BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 — — EP disclosed
WO-1998024771-A1 BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060567-A1 Novel indolyl derivatives which are L-CPT1 inhibitors CPT1A, CPT1B, CPT2 CHRM4 2294/4885DRD2 1295/4885HTR7 1562/4885
US-20240190847-A1 INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS DDR1, DDR2, DDRGK1 CHRM4 2460/4885DRD2 1284/4885HTR7 1766/4885
US-20230416251-A1 SPIROCYCLIC COMPOUNDS CRBN, RBX1, XIAP CHRM4 4547/4885DRD2 4192/4885HTR7 4056/4885
US-20030232860-A1 Medicine comprising dicyanopyridine derivative KCNN3, KCNN2, KCNN1 CHRM4 361/4885DRD2 1145/4885HTR7 1372/4885
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 CHRM4 2741/4885DRD2 1706/4885HTR7 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.